A Clinical Trial Assessing the Safety and Effectiveness of the DurAVR® THV System

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1650 participants.

Also called NCT07194265

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 1,650 participants (planned count) (from the registry)
Sponsor
Anteris Technologies Ltd. (from the registry)
Registry
  • NCT NCT07194265
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07194265. Randomized; single masking; primary purpose treatment. Start 2025-10-21 (actual); primary completion 2027-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Clinical Trial Assessing the Safety and Effectiveness of the DurAVR® THV System
Acronym
PARADIGM
Condition
Severe Aortic Stenosis
Condition
Valve-in-valve Procedures
Intervention (Device)
TAVR (transcatheter aortic valve replacement) with DurAVR® THV
Intervention (Device)
TAVR with SAPIEN THV series or the Evolut THV series
Lead sponsor
Anteris Technologies Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07194265
Content hash
527fa9dfe4a48d4162c9a139c0d2402bcad55e8e4b4b7b6b8328df642865e247